Pharmacokinetic study of gadolinium-DOTA in control and streptozocin diabetic rats.
The pharmacokinetics of gadolinium tetraazacyclododecanetetraacetic acid (Gd-DOTA), a contrast agent used in magnetic resonance imaging, have been evaluated in control and streptozocin-diabetic rats of different ages. In control rats, an age-related decrease in the Gd-DOTA elimination rate was noted, supported by a significantly lower apparent total body clearance and a significantly higher mean residence time. In diabetic rats, a similar but less important age-related change in the mean residence time and the apparent total body clearance was observed. Regardless of age-related differences in the pharmacokinetic parameters, a diabetic state induced several alterations in the Gd-DOTA pharmacokinetic parameters. The apparent total body clearance was significantly higher and the mean residence time significantly lower in diabetic rats indicating a higher elimination rate of Gd-DOTA. An important age-related increase in the volume of distribution at steady-state was noted in diabetic rats.
Laboratoire de pharmacodynamie, Faculté de Pharmacie, Montpellier, France.
A
A
Michel
P A
PA
Bonnet
J P
JP
Fernandez
C
C
Chambon
D
D
Doucet
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D006571:Heterocyclic Compounds / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
D001786:Blood Glucose; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate